Successful Phase 2 Study of IdeS in Highly Sensitized Dialysis Patients awaiting Kidney Transplantation
Hansa Medical AB today announced preliminary data showing that IdeS has very good efficacy in a phase 2 study with 8 highly sensitized patients on the waiting-list for kidney transplantation. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to acceptable levels. IdeS increased the probability of compatible transplantation by reducing the percentage panel reactivity to low levels in all patients.Hansa Medical AB today announced preliminary data showing that IdeS has very good efficacy in a phase 2 study with 8